Till Roehrich
About Till Roehrich
Till Roehrich serves as the Head of Pharmaceutical Development at The Siegfried Group, where he has worked since 2004. He has significantly contributed to the integration of chemistry and pharmaceutics and the development of active pharmaceutical ingredients.
Work at The Siegfried Group
Till Roehrich has served as the Head of Pharmaceutical Development at The Siegfried Group since 2004. His role is based in Wilmington, Delaware, where he has contributed to the company's growth for 20 years. Under his leadership, the pharmaceutical development team has focused on the development and manufacturing of active pharmaceutical ingredients and related intermediates. Roehrich has played a crucial role in enhancing the integration of chemistry and pharmaceutics within the organization.
Education and Expertise
Till Roehrich studied Chemistry at The University of Freiburg from 1983 to 1993, completing a decade of academic training. His educational background has provided him with a solid foundation in the principles of chemistry, which he applies in his current role in pharmaceutical development. His expertise encompasses both the scientific and practical aspects of pharmaceutical manufacturing.
Background
Roehrich has been a key figure at Siegfried Ltd., where he has contributed significantly to the development and production of finished dosage forms, including sterile fillings. His work involves overseeing the integration of various processes and ensuring that the pharmaceutical development aligns with industry standards and regulations. He is part of a larger team of approximately 2400 employees working across multiple countries, including Switzerland, Germany, France, Malta, China, and the USA.
Achievements
During his tenure at The Siegfried Group, Till Roehrich has been instrumental in advancing the company's capabilities in pharmaceutical development. His contributions have led to the successful integration of chemistry and pharmaceutics, enhancing the efficiency and effectiveness of the development process. His leadership has also facilitated the offering of comprehensive services in the production of active pharmaceutical ingredients and finished dosage forms.